Health Benefit Plans - Prescription Drugs - Rebates and Calculation of Cost Sharing Requirements
Impact
If enacted, SB 1019 would significantly alter how health benefit plans calculate enrollees' out-of-pocket contributions for prescription drugs, potentially lowering the immediate costs for consumers at the point of sale. This approach is intended to enhance transparency regarding the pricing of prescription drugs and how rebates influence overall costs. The 85% reduction in cost-sharing calculations promises to alleviate some financial burden on individuals who rely on these medications, especially those with chronic conditions requiring ongoing prescriptions.
Summary
Senate Bill 1019, introduced by Senator A. Washington, addresses the cost-sharing requirements for prescription drugs within health benefit plans. This bill mandates that the calculation of an enrollee's contribution towards their cost-sharing requirement be based on the list price of a prescription drug, reduced by at least 85% of the expected total amount of rebates received or anticipated from both carriers and pharmacy benefits managers. By doing so, the bill aims to provide clearer and more predictable costs to individuals when obtaining medications.
Contention
One key area of contention likely revolves around the prohibition of carriers and pharmacy benefits managers from making public the actual amounts they receive in rebates. Critics may argue that lacking transparency can hinder accountability and foster distrust among consumers regarding the true pricing of their medications. Additionally, concerns may arise about the financial implications for insurers and how these changes could affect their pricing structures and profitability. Furthermore, this measure could ignite debates on whether it adequately addresses the root causes of high drug prices or merely redistributes the costs.
Relating to the effect of certain reductions in a health benefit plan enrollee's out-of-pocket expenses for prescription drugs that are essential health benefits on the enrollee's cost-sharing requirements.
Relating to the effect of certain reductions in a health benefit plan enrollee's out-of-pocket expenses for prescription drugs that are essential health benefits on the enrollee's cost-sharing requirements.
Regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.